Latest & greatest articles for colorectal cancer

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on colorectal cancer or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on colorectal cancer and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for colorectal cancer

161. Improving Internal Medicine Residents’ Colorectal Cancer Screening Knowledge Using a Smartphone App: Pilot Study Full Text available with Trip Pro

Improving Internal Medicine Residents’ Colorectal Cancer Screening Knowledge Using a Smartphone App: Pilot Study Colorectal cancer (CRC) is the third most common type of cancer and the second leading cause of cancer death in the United States. About one in three adults in the United States is not getting the CRC screening as recommended. Internal medicine residents are deficient in CRC screening knowledge.The objective of our study was to assess the improvement in internal medicine residents (...) ' CRC screening knowledge via a pilot approach using a smartphone app.We designed a questionnaire based on the CRC screening guidelines of the American Cancer Society, American College of Gastroenterology, and US Preventive Services Task Force. We emailed the questionnaire via a SurveyMonkey link to all the residents of an internal medicine department to assess their knowledge of CRC screening guidelines. Then we designed an educational intervention in the form of a smartphone app containing all

2018 JMIR medical education

162. Oncolytic Adenoviruses in Gastrointestinal Cancers Full Text available with Trip Pro

Oncolytic Adenoviruses in Gastrointestinal Cancers Gastrointestinal malignancies are challenging cancers with considerable economic and societal impacts on health care systems worldwide. While advances in surgical approaches have provided benefits to a proportion of patients, only modest improvements have been attained in the treatment of patients with advanced disease, resulting in limited improvement in survival rates in these patients. Oncolytic adenoviruses are being developed to address (...) gastrointestinal malignancies. Each platform has evolved to maximize tumor-cell killing potency while minimizing toxicities. Tumor-specific bioengineered adenoviruses using chimeric promoters, prodrug convertase enzymes, lethal genes, tumor suppressor genes, and pseudo-typed capsids can provide the innovations for eventual success of oncolytic virotherapy. This article will review the developments in adenoviral platforms in the context of specific gastrointestinal cancers. From the bench to the implementation

2018 Biomedicines

163. Oral water soluble contrast for malignant bowel obstruction. Full Text available with Trip Pro

Oral water soluble contrast for malignant bowel obstruction. Malignant bowel obstruction (MBO) is a common problem in patients with intra-abdominal cancer. Oral water soluble contrast (OWSC) has been shown to be useful in the management of adhesive small bowel obstruction in identifying patients who will recover with conservative management alone and also in reducing the length of hospital stay. It is not clear whether the benefits of OWSC in adhesive small bowel obstruction are also seen (...) Index (Web of Science) and Conference Proceedings Citation Index - Science (Web of Science). We also searched registries of clinical trials and the CareSearch Grey Literature database. The date of the search was the 6 June 2017.Randomised controlled trials (RCTs), or prospective controlled studies, that evaluated the diagnostic potential of OWSC in predicting which malignant bowel obstructions will resolve with conservative treatment.RCTs, or prospective controlled studies, that assessed

2018 Cochrane

164. Surgery for metastatic gastrointestinal stromal tumor: to whom and how to? Full Text available with Trip Pro

Surgery for metastatic gastrointestinal stromal tumor: to whom and how to? Although imatinib is a standard treatment for metastatic or recurrent gastrointestinal stromal tumors (GISTs), acquired c-kit mutations reportedly cause secondary resistance to imatinib. Sunitinib is a tyrosine kinase inhibitor (TKI) that can be used as second-line therapy in imatinib-resistant or -intolerant GISTs. For sunitinib-resistant or -intolerant GISTs, regorafenib is a standard third-line treatment. Although TKI (...) surgery to be feasible in patients with metastatic GIST whose disease is stable or responsive to imatinib. Cytoreductive surgery may be indicated in limited disease progression refractory to imatinib when complete resection is possible, but case selection is critical. Cytoreductive surgery for metastatic GIST treated with sunitinib seems less feasible because of high rates of incomplete resections and complications. The role of cytoreductive surgery for metastatic GISTs would be difficult to establish

2018 Translational gastroenterology and hepatology

165. The Application of Gene Expression Profiling in Predictions of Occult Lymph Node Metastasis in Colorectal Cancer Patients Full Text available with Trip Pro

The Application of Gene Expression Profiling in Predictions of Occult Lymph Node Metastasis in Colorectal Cancer Patients A key factor in determining the likely outcome for a patient with colorectal cancer is whether or not the tumour has metastasised to the lymph nodes-information which is also important in assessing any possibilities of lymph node resection so as to improve survival. In this review we perform a wide-range assessment of literature relating to recent developments in gene (...) expression profiling (GEP) of the primary tumour, to determine their utility in assessing node status. A set of characteristic genes seems to be involved in the prediction of lymph node metastasis (LNM) in colorectal patients. Hence, GEP is applicable in personalised/individualised/tailored therapies and provides insights into developing novel therapeutic targets. Not only is GEP useful in prediction of LNM, but it also allows classification based on differences such as sample size, target gene

2018 Biomedicines

166. Lutathera (lutetium Lu 177 dotatate) Injection - To treat a type of cancer that affects the pancreas or gastrointestinal tract called gastroenteropancreatic neuroendocrine tumors (GEP-NETs).

Lutathera (lutetium Lu 177 dotatate) Injection - To treat a type of cancer that affects the pancreas or gastrointestinal tract called gastroenteropancreatic neuroendocrine tumors (GEP-NETs). Lutathera (lutetium Lu 177 dotatate) Injection U.S. Department of Health and Human Services Search FDA Submit search Lutathera (lutetium Lu 177 dotatate) Injection Lutathera Company: Advanced Accelerator Applications USA, Inc. Application No.: 208700 Approval Date: 01/26/2018 Persons with disabilities

2018 FDA - Drug Approval Package

167. Nivolumab (Opdivo) - metastatic colorectal cancer

expected to be used for the treatment of metastatic colorectal cancer (bowel cancer that has spread to other parts of the body) where the cancer had certain genetic changes (called ‘mismatch repair deficient’ or ‘microsatellite instability high’). It was to be used in adults who had previously been treated with fluoropyrimidines (a type of cancer medicines) together with other cancer medicines. How does Opdivo work? The active substance in Opdivo, nivolumab, is a monoclonal antibody, a protein that has (...) Nivolumab (Opdivo) - metastatic colorectal cancer 30 Churchill Place ? Canary Wharf ? London E14 5EU ? United Kingdom An agency of the European Union Telephone +44 (0)20 3660 6000 Facsimile +44 (0)20 3660 5555 Send a question via our website www.ema.europa.eu/contact © European Medicines Agency, 2018. Reproduction is authorised provided the source is acknowledged. 26 January 2018 EMA/51006/2018 EMEA/H/C/003985/II/0030 Withdrawal of the application for a change to the marketing authorisation

2018 European Medicines Agency - EPARs

168. Lymphocytic response to tumour and deficient DNA mismatch repair identify subtypes of stage II/III colorectal cancer associated with patient outcomes (Abstract)

Lymphocytic response to tumour and deficient DNA mismatch repair identify subtypes of stage II/III colorectal cancer associated with patient outcomes Tumour-infiltrating lymphocyte (TIL) response and deficient DNA mismatch repair (dMMR) are determinants of prognosis in colorectal cancer. Although highly correlated, evidence suggests that these are independent predictors of outcome. However, the prognostic significance of combined TIL/MMR classification and how this compares to the major genomic (...) and transcriptomic subtypes remain unclear.A prospective cohort of 1265 patients with stage II/III cancer was examined for TIL/MMR status and BRAF/KRAS mutations. Consensus molecular subtype (CMS) status was determined for 142 cases. Associations with 5-year disease-free survival (DFS) were evaluated and validated in an independent cohort of 602 patients.Tumours were categorised into four subtypes based on TIL and MMR status: TIL-low/proficient-MMR (pMMR) (61.3% of cases), TIL-high/pMMR (14.8%), TIL-low/dMMR

2018 EvidenceUpdates

169. Results of a Randomized, Double-Blind, Placebo-Controlled, Phase III Trial of Trifluridine/Tipiracil (TAS-102) Monotherapy in Asian Patients With Previously Treated Metastatic Colorectal Cancer: The TERRA Study (Abstract)

Results of a Randomized, Double-Blind, Placebo-Controlled, Phase III Trial of Trifluridine/Tipiracil (TAS-102) Monotherapy in Asian Patients With Previously Treated Metastatic Colorectal Cancer: The TERRA Study Purpose Trifluridine/tipiracil (TAS-102) was effective in patients with metastatic colorectal cancer (mCRC) in a phase II Japanese trial. This regional trial evaluated the efficacy and safety of trifluridine/tipiracil in Asian patients with mCRC with or without exposure to biologic (...) therapy. Patients and Methods This randomized, double-blind, placebo-controlled, phase III trial was conducted at 30 sites in China, the Republic of Korea, and Thailand. Patients ≥ 18 years old with histologically or cytologically confirmed adenocarcinoma of the colon or rectum and known KRAS status who were refractory or intolerant to two or more prior chemotherapy regimens were enrolled. Eligible patients were randomly assigned (2:1 ratio; minimization method) to receive trifluridine/tipiracil

2018 EvidenceUpdates

170. Micromanagement of drug-resistant advanced gastrointestinal stromal tumors: regorafenib—new ammunition in battling exon 17 mutations Full Text available with Trip Pro

Micromanagement of drug-resistant advanced gastrointestinal stromal tumors: regorafenib—new ammunition in battling exon 17 mutations 29552663 2018 11 14 2415-1289 3 2018 Translational gastroenterology and hepatology Transl Gastroenterol Hepatol Micromanagement of drug-resistant advanced gastrointestinal stromal tumors: regorafenib-new ammunition in battling exon 17 mutations. 12 10.21037/tgh.2018.02.01 Eckardt Alexander J AJ Department of Gastroenterology, DKD Helios Klinik Wiesbaden (...) -2018.02.01 PMC5847923 Ann Surg. 2000 Jan;231(1):51-8 10636102 J Clin Oncol. 2012 Jul 1;30(19):2401-7 22614970 N Engl J Med. 2002 Aug 15;347(7):472-80 12181401 Cancer Res Treat. 2017 Apr;49(2):350-357 27456941 Med Oncol. 2013 Jun;30(2):522 23456621 Lancet. 2013 Jan 26;381(9863):295-302 23177515 Eur J Cancer. 2014 Mar;50(5):981-6 24388774 Science. 1998 Jan 23;279(5350):577-80 9438854 World J Gastroenterol. 2017 Jul 21;23 (27):4856-4866 28785140 Ann Oncol. 2016 Sep;27(9):1794-9 27371698 Int J Clin Oncol

2018 Translational gastroenterology and hepatology

171. Exploratory pooled analysis evaluating the effect of sequence of biological therapies on overall survival in patients with RAS wild-type metastatic colorectal carcinoma Full Text available with Trip Pro

Exploratory pooled analysis evaluating the effect of sequence of biological therapies on overall survival in patients with RAS wild-type metastatic colorectal carcinoma The aim of this study was to evaluate the optimal sequence of targeted therapies (epidermal growth factor receptor inhibitors (EGFRi) and vascular endothelial growth factor inhibitors (VEGFi)), combined with chemotherapy, in patients with RAS wild-type (WT) metastatic colorectal carcinoma (mCRC). Exploratory analyses of overall (...) survival (OS) for patients treated with either first-line panitumumab (EGFRi) and second-line VEGFi therapy, or first-line bevacizumab (VEGFi) and second-line EGFRi, were conducted.Patients from PEAK (NCT00819780), PRIME (NCT00364013) and Study 181 (NCT00339183), with RAS WT or RAS WT/BRAF WT tumours, were included in the analyses. OS data were pooled for patients receiving first-line panitumumab (PEAK and PRIME) or first-line bevacizumab (PEAK and 181), followed by second-line VEGFi or EGFRi

2018 ESMO open

172. Prognostic indices of inflammatory markers, cognitive function and fatigue for survival in patients with localised colorectal cancer Full Text available with Trip Pro

Prognostic indices of inflammatory markers, cognitive function and fatigue for survival in patients with localised colorectal cancer Inflammation promotes the development of malignancy, while a variety of systemic markers of inflammation predict for worse cancer outcomes including recurrence and survival. Here, we evaluate the prognostic impact of cytokine concentrations, full blood count (FBC) differential ratios, cognitive function and fatigue on survival in patients with localised colorectal (...) of the cytokines (interleukin (IL-6), IL-1 and tumour necrosis factor) or differential ratios of blood components, fatigue or cognitive function was statistically related to DFS or OS. Patient educational status (P=0.018), stage of disease (P=0.032), alanine transaminase (P=0.003), lactate dehydrogenase (P=0.008) and carcinoembryonic antigen (P=0.002) were significant as prognostic covariates of OS in univariable analyses, with similar results for DFS.None of the a priori selected markers of inflammation

2018 ESMO open

173. Web-Based Communication Strategies Designed to Improve Intention to Minimize Risk for Colorectal Cancer: Randomized Controlled Trial Full Text available with Trip Pro

Web-Based Communication Strategies Designed to Improve Intention to Minimize Risk for Colorectal Cancer: Randomized Controlled Trial People seek information on the Web for managing their colorectal cancer (CRC) risk but retrieve much personally irrelevant material. Targeting information pertinent to this cohort via a frequently asked question (FAQ) format could improve outcomes.We identified and prioritized colorectal cancer information for men and women aged 35 to 74 years (study 1) and built (...) a website containing FAQs ordered by age and gender. In study 2, we conducted a randomized controlled trial (RCT) to test whether targeted FAQs were more influential on intention to act on CRC risk than the same information accessed via a generic topic list. Secondary analyses compared preference for information delivery, usability, relevance, and likelihood of recommendation of FAQ and LIST websites.Study 1 determined the colorectal cancer information needs of Australians (N=600) by sex and age group

2018 JMIR cancer Controlled trial quality: uncertain

174. SWOG study shows significant long-term overall survival for advanced gastrointestinal stromal tumor patients with imatinib treatment Full Text available with Trip Pro

SWOG study shows significant long-term overall survival for advanced gastrointestinal stromal tumor patients with imatinib treatment 29552661 2018 11 14 2415-1289 3 2018 Translational gastroenterology and hepatology Transl Gastroenterol Hepatol SWOG study shows significant long-term overall survival for advanced gastrointestinal stromal tumor patients with imatinib treatment. 10 10.21037/tgh.2018.01.09 Trautmann Marcel M Gerhard-Domagk-Institute of Pathology, University Hospital Münster (...) Cancer. 2014 Aug;21(4):567-77 24859990 J Clin Oncol. 2008 Nov 20;26(33):5360-7 18955451 J Gastrointest Surg. 2012 Sep;16(9):1645-7 22752549 Science. 1998 Jan 23;279(5350):577-80 9438854 Clin Cancer Res. 2008 Jul 15;14(14):4550-5 18628470 Ann Oncol. 2010 May;21 Suppl 5:v98-102 20555113 Mod Pathol. 2013 Jul;26(7):1004-12 23599150 Am J Gastroenterol. 2005 Jan;100(1):162-8 15654796 J Clin Oncol. 2010 Mar 1;28(7):1247-53 20124181 Cancer. 2005 Feb 15;103(4):821-9 15648083 Expert Rev Anticancer Ther. 2015

2018 Translational gastroenterology and hepatology

175. Asian consensus guidelines for gastrointestinal stromal tumor: what is the same and what is different from global guidelines Full Text available with Trip Pro

Asian consensus guidelines for gastrointestinal stromal tumor: what is the same and what is different from global guidelines There are some disparities between the clinical practice and profiles of cancer in Asia and those in Europe & North America. In Asia, surgical oncologists still have a major role in the multidisciplinary therapy of gastrointestinal stromal tumor (GIST), whereas medical oncologists hold this status in the West. Although the incidence of clinical GIST is considered similar (...) between the two areas, small gastric GISTs are more frequently treated by surgery in East Asia compared with Europe & North America. The diagnosis and treatment of small submucosal tumors (SMTs), including GIST, is important in Asian clinical practice guidelines for GIST. Most items of Asian and Western GIST guidelines are very similar. There are slight differences between the two guidelines in the degree of recommendation, which may come from disparities of clinical practice and available medicines

2018 Translational gastroenterology and hepatology

176. Rosiglitazone diminishes the high-glucose-induced modulation of 5-fluorouracil cytotoxicity in colorectal cancer cells Full Text available with Trip Pro

Rosiglitazone diminishes the high-glucose-induced modulation of 5-fluorouracil cytotoxicity in colorectal cancer cells Colorectal cancer (CRC) is the third most leading cause of morbidity and mortality throughout the world. 5-fluorouracil (5-FU), which is often administrated to disrupt carcinogenesis, was found to elevate blood glucose level among CRC patients. Thus, this study was conducted to evaluate the influence of rosiglitazone on antiproliferative effect of 5-FU using cellular model. Two (...) human colonic carcinoma cell lines (HCT 116 and HT 29) were cultured in the presence of 5-FU, rosiglitazone or in combination under normal and high glucose concentration. The drug cytotoxicity was evaluated using the MTT assay whereas the assessment of cell cycle was carried out using the flow cytometry technique. Combination index (CI) method was used to determine the drug interaction between rosiglitazone and 5-FU. High glucose diminished the cytotoxic effect of 5-FU but at a high drug dosage

2018 EXCLI journal

177. Bevacizumab (Mvasi) - Cancer, colon, breast, lung, kidney, ovary, cervix

(EMA) for MVASI, through the centralised procedure falling within the Article 3(1) and point 1 of Annex of Regulation (EC) No 726/2004. The applicant applied for the following indications: MVASI in combination with fluoropyrimidine-based chemotherapy is indicated for treatment of adult patients with metastatic carcinoma of the colon or rectum. MVASI in combination with paclitaxel is indicated for first-line treatment of adult patients with metastatic breast cancer. For further information (...) of cytotoxic chemotherapy (Goel et al, 2011). The Applicant claimed the same therapeutic indications and posology for the proposed biosimilar Mvasi as granted for Avastin in the European Union (EU): • MVASI in combination with fluoropyrimidine-based chemotherapy is indicated for treatment of adult patients with metastatic carcinoma of the colon or rectum. • MVASI in combination with paclitaxel is indicated for first-line treatment of adult patients with metastatic breast cancer. Assessment report EMA

2018 European Medicines Agency - EPARs

178. Infliximab treatment in inflammatory bowel disease does not increase the risk of malignancy

Publication date: 18/10/2017 Abstract Authors’ conclusions: exposure to infliximab is not associated with an increased risk of malignancy or hemophagocytic syndrome in children with inflammatory bowel disease. Exposure to thiopurines is an important antecedent for the development of these complications. Reviewers’ commentary: the use of infliximab and other biological therapies does not seem to increase the risk of onset of tumors in the medium term, although it would be advisable to prolong the follow-up (...) Infliximab treatment in inflammatory bowel disease does not increase the risk of malignancy Infliximab treatment in inflammatory bowel disease does not increase the risk of malignancy - Evidencias en pediatría Searching, please wait Show menu Library Management You did not add any article to your library yet. | Search Evidence-Based decision making Evidence-Based decision making Show menu Library Management You did not add any article to your library yet. × User Password Log in × Reset password

2018 Evidencias en Pediatría

179. Management of rectal gastrointestinal stromal tumor Full Text available with Trip Pro

Management of rectal gastrointestinal stromal tumor Gastrointestinal stromal tumor (GIST) is the most common mesenchymal neoplasm of the gastrointestinal tract. However, rectal GIST is rare, the incident rate of it is approximately 5% of all GISTs. Rectal GIST symptoms generally include bleeding and/or pain and occasionally, urinary symptoms. Immunohistochemical evaluation finds that most rectal GIST tumors are CD117 (KIT) positive, and are sometimes CD34, platelet-derived growth factor (...) receptor alpha (PDGFRA), smooth muscle actin, S-100, or vimentin positive. The National Institutes of Health (NIH) classifies rectal GIST as very-low risk, low risk, intermediate risk, or high risk, and the frequencies have been estimated as 0-23.8% for very-low risk, 0-45% for low risk, 0-34% for intermediate risk, and 21-100% for high risk tumors. The first-line treatment for localized GIST is curative resection, but is difficult in rectal GIST because of anatomical characteristics such as the deep

2018 Translational gastroenterology and hepatology

180. Lonsurf for Metastatic Colorectal Cancer – Details

Lonsurf for Metastatic Colorectal Cancer – Details Lonsurf for Metastatic Colorectal Cancer – Details | CADTH.ca Find the information you need Lonsurf for Metastatic Colorectal Cancer – Details Lonsurf for Metastatic Colorectal Cancer – Details Project Number pCODR 10122 Brand Name Lonsurf Generic Name Trifluridine and Tipiracil Strength 15 mg & 20 mg Tumour Type Gastrointestinal Indication Metastatic Colorectal Cancer Funding Request For the treatment of adult patients with metastatic (...) colorectal cancer who have been previously treated with, or are not considered candidates for, available therapies including fluoropyrimidine-, oxaliplatin- and irinotecan-based chemotherapies, anti-VEGF agents, and anti-EGFR agents Review Status Notification to Implement Issued Pre Noc Submission Yes NOC Date January 25, 2018 Manufacturer Taiho Pharma Canada, Inc. Submitter Taiho Pharma Canada, Inc. Submission Date November 6, 2017 Submission Deemed Complete November 13, 2017 Submission Type New Drug

2018 CADTH - Pan Canadian Oncology Drug Review